Novo Nordisk A/S found using ticker (NVO) have now 2 analysts in total covering the stock. The consensus rating is ‘Buy’. The range between the high target price and low target price is between 119.42 and 115.6 with a mean TP of 117.51. Now with the previous closing price of 106.59 this would imply there is a potential upside of 10.2%. The 50 day moving average now sits at 105.57 and the 200 day MA is 96.42. The company has a market capitalisation of $241,602m. Find out more information at: https://www.novonordisk.com
The potential market cap would be $266,354m based on the market concensus.
Novo Nordisk A/S, a healthcare company, engages in the research, development, manufacture, and marketing of pharmaceutical products worldwide. It operates in two segments, Diabetes and Obesity care, and Biopharm. The Diabetes and Obesity care segment provides products in the areas of insulins, GLP-1 and related delivery systems, oral antidiabetic products, obesity, and other chronic diseases. The Biopharmaceuticals segment offers products in the areas of haemophilia, growth disorders, and hormone replacement therapy. The company collaboration agreements with Gilead Sciences Novo Nordisk A/S also has a research collaboration with Lumen Bioscience to explore strategies for delivering oral biologics for cardiometabolic disease. The company was founded in 1923 and is headquartered in Bagsvaerd, Denmark.
